Clinical applications of molecular imaging in sarcoma evaluation

Cancer Imaging

Volumn 5, Issue 1, 2005, Pages 66-72

  Hicks, Rodney J ^a,b   Toner, Guy C ^a,b   Choong, Peter F M ^b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

201Tl; Biopsy guidance; FDG; Grading; PET; Therapy monitoring

Indexed keywords

CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; NEEDLE BIOPSY; POSITRON EMISSION TOMOGRAPHY; REVIEW; SARCOMA;

BIOPSY, NEEDLE; HUMANS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; SARCOMA; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33645270433     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2005.0008     Document Type: Article

References (44)

1. Ballo MT, Zagars GK. Radiation therapy for soft tissue sarcoma. Surg Oncol Clin N Am 2003; 12: 449-67, vii (review).
2. Phan A, Patel S. Advances in neoadjuvant chemotherapy in soft tissue sarcomas. Curr Treat Options Oncol 2003; 4: 433-9.
3. Bacci G, Lari S. Current treatment of high grade osteosarcoma of the extremity: review. J Chemother 2001; 13: 235-43.
4. Hicks RJ. Functional imaging techniques for evaluation of sarcomas. Cancer Imaging 2005; 5 (doi: 10.1102/14707330.2005.0007).
5. Choong PF, Kunisada T, Slavin J, Schlicht S, Hicks R. The role of thallium-201 and pentavalent dimercaptosuccinic acid for staging cartilaginous tumours. Int Semin Surg Oncol 2004; 1: 10 (DOI:10.1186/1477-7800-1-10).
6. Townsend DW, Beyer T, Blodgett TM. PET/CT scanners: a hardware approach to image fusion. Semin Nucl Med 2003; 33: 193-204.
7. Shives TC. Biopsy of soft-tissue tumors. Clin Orthop Relat Res 1993; 289: 32-5.
8. Brown FM, Fletcher CD. Problems in grading soft tissue sarcomas. Am J Clin Pathol 2000; 114: S82-9.
9. Oliveira AM, Nascimento AG. Grading in soft tissue tumors: principles and problems. Skeletal Radiol 2001; 30: 543-59.
10. Folpe AL, Lyles RH, Sprouse JT, Conrad EU 3rd, Eary JF. (F-18)Fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res 2000; 6: 1279-87.
11. Ramanna L, Waxman A, Binney G, Waxman S, Mirra J, Rosen G. Thallium-201 scintigraphy in bone sarcoma: comparison with gallium-67 and technetium-MDP in the evaluation of chemotherapeutic response. JNucl Med 1990; 31: 567-72.
12. Di Chiro. Positron emission tomography using [F]fluorodeoxy glucose in brain tumors. A powerful diagnostic and prognostic tool. Invest Radiol 1986; 22: 720-8.
13. Adler LP, Blair HF, Makley JT et al. Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med 1991; 32: 1508-12.
14. Jones DN, McCowage GB, Sostman HD et al. Monitoring neoadjuvant therapy response of soft tissue and musculoskeletal sarcoma with fluorine-18-FDG PET. J Nucl Med 1996; 37: 1438-44.
15. Schulte M, Brecht-Krauss D, Heymer B et al. Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET. J Nucl Med 2000; 41: 1695-701.
16. Schulte M, Brecht-Krauss D, Heymer B et al. Fluorodeoxyglucose positron emission tomography of soft tissue tumours: is a non-invasive determination of biological activity possible? Eur J Nucl Med 1999; 26: 599-605.
17. Bastiaannet E, Groen H, Jager PL et al. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev 2004; 30: 83-101.
18. Nieweg OE, Pruim J, van Ginkel RJ et al. Fluorine-18- fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med 1996; 37: 257-61.
19. Aoki J, Watanabe H, Shinozaki T et al. FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. Radiology 2001; 219: 774-7.
20. Kobayashi H, Kotoura Y, Hosono M et al. Diagnostic value of Tc-99m (V) DMSA for chondrogenic tumours with positive Tc-99m HMDP uptake on bone scintigraphy. Clin Nucl Med 1995; 20: 361-4.
21. Abe H, Terui S, Terauchi T et al. Comparison of Tc-99m pertechnetate with Tl-201 and Ga-67 scintigraphy of malignant soft-tissue tumors. Clin Nucl Med 1997; 22: 38-41.
22. Brenner W, Conrad EU, Eary JF. FDG PET imaging for grading and prediction of outcome in chondrosarcoma patients. Eur J Nucl Med Mol Imaging 2004; 31: 189-95.
23. Eary JF, O'Sullivan F, Powitan Y et al. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging 2002; 29: 1149-54.
24. Cobben DC, Elsinga PH, Suurmeijer AJ et al. Detection and grading of soft tissue sarcomas of the extremities with F-3'-fluoro-3'-deoxy-L-thymidine. Clin Cancer Res 2004; 10: 1685-90.
25. Caluser CI, Abdel-Dayem HM, Macapinlac HA et al. The value of thallium and three-phase bone scans in evaluation of bone and soft tissue sarcomas. Eur JNucl Med 1994; 21: 1198-205.
26. Franzius C, Daldrup-Link HE, Sciuk J et al. FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann Oncol 2001; 12: 479-86.
27. Raymond AK, Chawla SP, Carrasco CH et al. Osteosarcoma chemotherapy effect: a prognostic factor. Semin Diagn Pathol 1987; 4: 212-36.
28. Shapeero LG, Vanel D. Imaging evaluation of the response of high-grade osteosarcoma and Ewing sarcoma to chemotherapy with emphasis on dynamic contrast-enhanced magnetic resonance imaging. Semin Musculoskelet Radiol 2000; 4: 137-46.
29. Lin J, Leung WT, Ho SK et al. Quantitative evaluation of thallium-201 uptake in predicting chemotherapeutic response of osteosarcoma. Eur J Nucl Med 1995; 22: 553-5.
30. Ohtomo K, Terui S, Yokoyama R et al. Thallium-201 scintigraphy to assess effect of chemotherapy in osteosarcoma. J Nucl Med 1996; 37: 1444-8.
31. Menendez LR, Fideler BM, Mirra J. Thallium-201 scanning for the evaluation of osteosarcoma and soft-tissue sarcoma. A study of the evaluation and predictability of the histological response to chemotherapy. J Bone Joint Surg Am 1993; 75: 526-31.
32. Maini CL, Tofani A, Sciuto R et al. Thallium-201 scintigraphy and chemotherapeutic response in rhabdomyosarcoma. Clin Nucl Med 1994; 19: 607-10.
33. Choong PF, Nizam I, Ngan SY et al. Thallium-201 scintigraphy-a predictor of tumour necrosis in soft tissue sarcoma following preoperative radiotherapy? Eur J Surg Oncol 2003; 29: 908-15.
34. Söderlund V, Jonsson C, Bauer HC, Brosjö O, Jacobsson H. Comparison of technetium-99m-MIBI and technetium-99m-tetrofosmin uptake by musculoskeletal sarcomas. J Nucl Med 1997; 38: 682-6.
35. Slosman DO, Pugin J. Lack of correlation between tritiated deoxyglucose, thallium-201 and technetium-99m-MIBI cell incorporation under various cell stresses. J Nucl Med 1994; 35: 120-6.
36. Garcia R, Kim EE, Wong FC, Korkmaz M, Wong WH, Yang DJ, Podoloff DA. Comparison of fluorine-18-FDG PET and technetium-99m-MIBI SPECT in evaluation of musculoskeletal sarcomas. J Nucl Med 1996; 37: 1476-9.
37. Haberkorn U, Strauss LG, Dimitrakopoulou A et al. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med 1991; 32: 1485-90.
38. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer using positron emission tomography: initial experience. J Clin Oncol 1993; 11: 2101-11.
39. Huovinen R, Leskinen-Kallio S, Nagren K et al. Carbon-11-methionine and PET in evaluation of treatment response in breast cancer. Br J Cancer 1993; 67: 787-91.
40. Schulte M, Brecht-Krauss D, Werner M et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med 1999; 40: 1637-43.
41. Franzius C, Sciuk J, Brinkschmidt C, Jurgens H, Schober O. Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis. Clin Nucl Med 2000; 25: 874-81.
42. Nair N, Ali A, Green AA et al. Response of osteosarcoma to chemotherapy. Evaluation with F-18 FDG-PET scans. Clin Positron Imaging 2000; 3: 79-83.
43. Kostakoglu L, Panicek DM, Divgi CR et al. Correlation of the findings of thallium-201 chloride scans with those of other imaging modalities and histology following therapy in patients with bone and soft tissue sarcomas. Eur J Nucl Med 1995; 22: 1232-7.
44. Inoue T, Kim EE, Wong FC et al. Comparison of fluorine-18- fluorodeoxyglucose and C-11-methionine PET in detection of malignant tumors. J Nucl Med 1996; 37: 1472-6.